Presentation
This preindication aims to unify a significant number of rare diseases that include cerebral calcifications as a phenotypic gateway, providing a critical element for interpreting sequencing data. The clinical presentation can be heterogeneous, and widespread access to brain imaging makes it possible to identify a clinical-radiological entity that will facilitate interpretation.
Criteria before considering a discussion in MDM-FMG
Patients presenting neurological and/or psychiatric symptoms related to:
- Cerebral calcifications affecting at least the basal ganglia,
- of greater extent and severity than would be expected for their age (if necessary: TCS visual scan scale and normative data: Nicolas et al., Brain 2013),
- and in the absence of calcium-phosphorus metabolism disorders (at least: PTH, blood vitamin D, calcium, phosphorus)
- OR calcifications of the white matter and/or cerebral cortex in the absence of calcifications of the basal ganglia
- OR pontocerebellar calcifications in the absence of calcifications of the basal ganglia
- Excluding clinically severe paediatric forms (current age < 5 years)
Genome Sequencing in diagnostic strategy

MDM Neurogenetics Paris Pitié
Claire EWENCZYK
Alexandra DURR
Perrine CHARLES
Anna HEINZMANN
MDM Neurogenetics Paris Trousseau
MDM Neurogenetics Angers
MDM Neurogenetics Strasbourg
Mathieu ANHEIM
mathieu.anheim@chru-strasbourg.fr
Christine TRANCHANT
christine.tranchant@chru-strasbourg.fr
Solène FRISMAND
Matthieu BEREAU
Christel THAUVIN
Anne DOE DE MAINDREVILLE
adoedemaindreville@chu-reims.fr
Juliette PIARD
MDM Neurogenetics Montpellier
MDM Neurogenetics Lille
